8-K/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

FORM 8-K/A

(Amendment No. 1)

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  September 2, 2010

                          AMERICAN BIO MEDICA CORPORATION                         

(Exact name of registrant as specified in its charter)

New York	0-28666	14-1702188
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

122 Smith Road, Kinderhook, NY	12106
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code:  518-758-8158

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Explanatory Note: This current report on Form 8-K/A amends the current report on Form 8-K (the “Original Form 8-K”) filed by American Bio Medica Corporation (the “Company”) with the U.S. Securities and Exchange Commission on August 20, 2010. The Original Form 8-K reported an error in the new base salary of the Company’s Chief Financial Officer and Executive Vice President, Finance Stefan Parker.  The correct disclosure follows:

On August 18, 2010, the Board of Directors of American Bio Medica Corporation (the “Company”), upon recommendation of the Compensation Committee of the Company and upon motion duly made, seconded and carried unanimously, adopted a resolution to increase the base salary of the Company’s Chief Financial Officer and Executive Vice President, Finance Stefan Parker (“Parker”) from $120,000 on an annualized basis to $135,000 on an annualized basis. The increase in base salary is effective August 30, 2010. All other respects of Parker’s employment letter dated August 22, 2007 remain unchanged and in full force and effect.

Item 9.01  Financial Statements and Exhibits

(d)    Exhibits

10.33.1     Letter Amending Employment Letter between the Company and Stefan Parker

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AMERICAN BIO MEDICA CORPORATION (Registrant)
Dated: September 3, 2010	By:	/s/ Melissa A. Waterhouse
		Melissa A. Waterhouse
		Vice President & Chief Compliance Officer
		Corporate Secretary

EX-10.33.1

EXHIBIT 10.33.1

August 18, 2010

Stefan Parker

5 Wood Duck Place

Waterford, NY 12188

Dear Stefan,

On August 18, 2010, the Compensation Committee of the American Bio Medica Corporation (“ABMC” or the “Company”) Board of Directors recommended that the base salary outlined in your August 22, 2007 employment letter (the “Employment Letter”) be increased from $120,000 on an annualized basis, to $135,000 on an annualized basis. Upon consideration of this recommendation, the Board of Directors of the Company, upon a duly made, seconded and unanimously carried motion, adopted a resolution that your base salary be increased to $135,000 on an annualized basis.

This letter shall serve as an amendment to your Employment Letter. More specifically, the following term shall be amended as follows:

Compensation

Effective August 30, 2010, your base salary will be $11,250.00 per month, which is equivalent to $135,000 on an annualized basis.  You will be eligible for your first performance review by the Board of Directors in August 2011.

If you so desire, the cost of your health insurance (including family coverage if you so require) shall be borne 100% by the Company.  Please notify Human Resources if you wish to receive this benefit.

You shall receive a car allowance of $10,000 per year, to be paid on a monthly basis and subject to tax on your part, and reimbursement for any approved company related expenses.

You shall participate in the Management Bonus Program as approved by the Board of Directors on January 19, 2005, and as amended by the Board of Directors on November 9, 2005.

In all other respects your Employment Letter shall remain in full force and effect and unaltered.

Sincerely,

/s/ Stan Cipkowski

Stan Cipkowski

Chief Executive Officer

By order of the American Bio Medica Corporation Board of Directors

Accepted this 18th Day of August, 2010:

/s/ Stefan Parker

Stefan Parker